Unlocking a new targeted approach to cancer
Learn more about how we are advancing new options for patientsZentalis is developing a differentiated oral therapy that targets WEE1 kinase, a key regulator of cell-cycle progression. WEE1 kinase inhibition is a novel approach that breaks down the safeguards that cancer cells use to survive.
Bringing unmatched WEE1 expertise, Zentalis is focused on azenosertib, an investigational drug with the potential to provide physicians and patients with a choice for a targeted, oral therapy, where few non-chemotherapy options exist today.
Zentalis is advancing the first oral, non-chemotherapy, biomarker-driven approach specifically for Cyclin E1 positive platinum-resistant ovarian cancer patients to transform decades of WEE1 research into a novel targeted therapy option.
Our mission is clear: to unburden patients through a more convenient, targeted approach to cancer care.
Azenosertib leads the WEE1 targeting field and is currently in registration-intended studies.
We have built a focused pipeline in late-stage clinical development.
Led by experience: a disciplined leadership team with a proven track record in oncology innovation.
